Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary C Birmingham

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Pediatric Emergency Care|September 1, 2011
Screening for postpartum depression in a pediatric emergency departmentMary C Birmingham, Katherine J Chou, Ellen F Crain
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Clinical Pharmacokinetics|December 17, 2003
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programmeCraig R Rayner, Alan Forrest, Alison K Meagher, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Population pharmacokinetics of linezolid in patients treated in a compassionate-use programAlison K Meagher, Alan Forrest, Craig R Rayner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programMary C Birmingham, Craig R Rayner, Alison K Meagher, et al.
Journal of Cardiac Failure|April 11, 2023
Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) TrialMichael Nassif, Mary C Birmingham, David E Lanfear, et al.
Nature Medicine|March 1, 2022
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trialJohn A Spertus, Mary C Birmingham, Michael Nassif, et al.
Circulation. Heart Failure|March 16, 2021
Novel Trial Design: CHIEF-HFJohn A Spertus, Mary C Birmingham, Javed Butler, et al.
American Heart Journal|March 7, 2021
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trialMintu Turakhia, Vandana Sundaram, Shea N Smith, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Pediatric Emergency Care|September 1, 2011
Screening for postpartum depression in a pediatric emergency departmentMary C Birmingham, Katherine J Chou, Ellen F Crain
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Clinical Pharmacokinetics|December 17, 2003
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programmeCraig R Rayner, Alan Forrest, Alison K Meagher, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Population pharmacokinetics of linezolid in patients treated in a compassionate-use programAlison K Meagher, Alan Forrest, Craig R Rayner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2003
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programMary C Birmingham, Craig R Rayner, Alison K Meagher, et al.
Journal of Cardiac Failure|April 11, 2023
Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) TrialMichael Nassif, Mary C Birmingham, David E Lanfear, et al.
Nature Medicine|March 1, 2022
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trialJohn A Spertus, Mary C Birmingham, Michael Nassif, et al.
Circulation. Heart Failure|March 16, 2021
Novel Trial Design: CHIEF-HFJohn A Spertus, Mary C Birmingham, Javed Butler, et al.
American Heart Journal|March 7, 2021
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trialMintu Turakhia, Vandana Sundaram, Shea N Smith, et al.
Pageof 2